Aspira Women's Health Inc. AWHL
0.26
0.00
0.00%
as of 25 Sep
- Market cap
- $2.4M
- P/E
- 0.0×
Follow AWHL
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.91 | 2.33 | 1.76 | 2.12 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(84.10) | (10.85) | (43.61) | (9.03) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.64 | 2.33 | 1.95 | 2.29 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.53) | (3.06) | (4.06) | (4.30) | |
EV/FCF |
(2.52) | (3.05) | (4.04) | (4.15) | |
Quick Ratio |
1.22 | 0.85 | 0.49 | 0.37 | |
Current Ratio |
1.39 | 1.17 | 0.68 | 0.52 | |
Net Debt/EBITDA |
1.62 | (0.01) | (0.81) | (0.82) | |
Debt/Assets |
18.28% | 32.44% | 60.75% | 43.88% | |
Debt/Equity |
(0.31) | (0.26) | (0.50) | (0.27) | |
Asset Turnover |
1.55 | 1.68 | 1.51 | 1.82 | |
Operating CF/Net income |
0.04 | 0.59 | (0.53) | 0.83 | |
Capex/Depreciation |
(7.86) | (0.21) | 0.00 | (3.75) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
32.06% | 20.74% | 62.33% | 33.82% | |
Selling, General and Administrative Expense of Revenue |
96.44% | 101.44% | 104.12% | 111.14% | |
Intangible Assets out of Total Assets |
0.05 | 0.06 | 0.05 | 0.06 | |
Share Based Compensation of Revenue |
1.56% | 16.88% | 2.14% | 0.93% | |
Graham Net Nets |
(0.33) | (0.39) | (0.48) | (0.49) | |
Graham Number |
1.00 | 1.30 | 0.92 | 0.95 | |
Earnings Yield |
(75.51%) | (58.65%) | (73.33%) | (59.51%) | |
Free Cash Flow Yield |
(34.18%) | (32.80%) | (27.49%) | (26.06%) | |
Revenue per Share |
0.06 | 0.07 | 0.05 | 0.05 | |
Operating CF per Share |
(0.01) | (0.06) | (0.01) | (0.05) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.06) | (0.01) | (0.05) | |
Cash per Share |
0.10 | 0.05 | 0.03 | 0.01 | |
Shareholders Equity per Share |
(0.12) | (0.20) | (0.14) | (0.16) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.12) | (0.20) | (0.14) | (0.16) | |
Free Cash Flow |
(0.60) | (1.99) | (0.36) | (2.16) | |
Working Capital |
1.63 | 0.60 | (1.81) | (2.54) | |
Capital Expenditures |
(0.39) | (0.01) | — | (0.15) | |
Net Current Asset Value |
(5.81) | (8.32) | (7.51) | (8.89) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.17 | 0.00 | 0.00 | 0.07 | |
Net Profit Margin |
(212.23%) | (151.21%) | 34.37% | (118.28%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.29 | 1.10 | 1.26 | 1.38 | |
Average Payables |
2.18 | 1.71 | 1.71 | 2.25 | |
Average Inventory |
0.29 | 0.29 | 0.28 | 0.25 | |
Average Assets |
6.03 | 5.47 | 5.90 | 4.68 | |
Average Common Equity |
(3.43) | (4.75) | (3.13) | (4.97) |
Columns are period end dates